Article

Biocompatible Core–Shell-Structured Si-Based NiO Nanoflowers and Their Anticancer Activity

Kihak Gwon 1,2,†, Jong-Deok Park 3,4, Seonhwa Lee 1, Jong-Sung Yu 3,∗ and Do Nam Lee 1,∗

1 Ingenium College of Liberal Arts (Chemistry), Kwangwoon University, Seoul 01897, Korea; khgwon@kw.ac.kr (K.G.); seonhwalee@kw.ac.kr (S.L.)
2 Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55902, USA
3 Department of Energy Science and Engineering, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea; jd3388@dgist.ac.kr
4 Correspondence: jsyu@dgist.ac.kr (J.-S.Y.); donamlee2@kw.ac.kr (D.N.L.)
† These authors contributed equally to this work.

Abstract: Compared to most of nano-sized particles, core–shell-structured nanoflowers have received great attention as bioactive materials because of their high surface area with the flower-like structures. In this study, core–shell-structured Si-based NiO nanoflowers, Si@NiO, were prepared by a modified chemical bath deposition method followed by thermal reduction. The crystal morphology and basic structure of the composites were characterized by powder X-ray diffraction (PXRD), Fourier-transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), transmission electron microscopy (TEM), specific surface area (BET) and porosity analysis (BJT), and inductively coupled plasma optical emission spectrometry (ICP-OES). The electrochemical properties of the Si@NiO nanoflowers were examined through the redox reaction of ascorbic acid with the metal ions present on the surface of the core–shell nanoflowers. This reaction favored the formation of reactive oxygen species. The Si@NiO nanoflowers showed excellent anticancer activity and low cytotoxicity toward the human breast cancer cell line (MCF-7) and mouse embryonic fibroblasts (MEFs), respectively, demonstrating that the anticancer activities of the Si@NiO nanoflowers were primarily derived from the oxidative capacity of the metal ions on the surface, rather than from the released metal ions. Thus, this proves that Si-based NiO nanoflowers can act as a promising candidate for therapeutic applications.

Keywords: core–shell; Ni composite; nanoflowers; biocompatibility; anticancer activity

1. Introduction

Cancer is a disease that is associated with abnormal cell growth and can spread to other parts of the body. Globally, cancer-associated deaths are only second in number after deaths related to cardiovascular diseases and are considered the most critical global health issue. Conventional drugs and diagnostics for cancer therapies suffer from poor absorption from target sites, require repeated dosing, and are associated with high dose dumping. Consequently, a new and improved technology is required for effective therapeutic drug loading and theranostics to ensure suitable diagnostics in pre-stage cancer [1–3]. At present, healthcare providers and researchers are working in communion to develop effective cancer therapies [4]. Nanotechnology-based drug systems and theranostics are commonly based on nanoparticles (NPs) that are 10–1000 nm in size, and various nanotechnologies based on liposomes, micelles, dendrimers, CNFs, quantum dots, and other composites have been developed to enhance the efficacy of drugs, improving the solubility of hydrophobic drugs and adequately controlling the drug release [5–13]. NPs have unique and favorable properties that are different from those of bulk materials in terms of drug toxicity and biodistribution. Due to its outstanding features, nanotechnology has emerged as a new solution for cancer therapy. However, the small sizes of the NPs may occasionally have adverse effects because of nonspecific accumulation in the organs, including in the liver, spleen,
and lung, resulting in cytotoxicity [14,15]. This has hindered the extensive application of various NPs in cancer therapy, although a variety of nano drugs, including Doxil®, Eligard®, Abraxanes®, Genexol PM®, and Onivyde®, have been approved by the FDA [16–20]. The suitability of noble metal NPs, including Ag, Au, and Pt NPs, as biomaterials has been intensively studied for therapeutic treatments [21–25]. On the other hand, metal oxides such as CuO, ZnO, TiO$_2$, and NiO have been introduced as new alternatives that exhibit good antimicrobial activities [26–30]. In particular, ZnO NPs are widely used in cancer therapy, as they are toxic to cancer cells; however, they show high cytotoxicity at high doses. The methylation of histidine resulted in increased anticancer activity at low doses for bladder cancer T-24 cells, leading to the discovery of a novel epigenetic mechanism with low toxicity at low concentrations of ZnO [31–33]. Furthermore, metal oxide NPs containing Fe, Co, and Ni are of great interest due to their unique optical, electronic, and physiochemical properties that can be harnessed in various fields such as photo catalysis, drug delivery, catalysis, magnetic resonance imaging, and cancer therapy [34–41]. In nanotechnology, particle size and morphology are crucial for determining the potency for medicinal applications [42–45]. NiO NPs exhibit excellent cytotoxic effects due to their unique properties, such as metal ion release, high surface area to volume ratio, enhanced adsorbing ability, and lower toxicity, compared to other metal oxides exhibiting anticancer activity [46]. Compared to nanostructures such as nanospheres or nanorods, nanoflower-like structures with different petals provide high surface areas [43,47,48]. However, a survey of the literature indicates that only a few studies have investigated metal oxide-based nanoflowers for anticancer reagents.

In this study, we explored new flower-like NiO NPs that exhibited high anticancer activity and low cytotoxicity. Core–shell-structured Si-based NiO (Si@NiO) nanoflowers were prepared by a modified chemical deposition method followed by thermal reduction. Their physical and electrochemical properties were investigated using various microscopic, spectroscopic, and electrochemical techniques. The therapeutic potential of the Si@NiO nanoflowers was investigated by testing the viability of the human breast cancer cell line MCF-7 in the presence of Si@NiO and the cytotoxicity of Si@NiO toward mouse embryonic fibroblasts (MEFs). The potential therapeutic properties of Si@NiO and its anticancer mechanism are presented.

2. Materials and Methods
2.1. Synthesis of Si@NiO Nanoflowers

Si@NiO nanoflowers were synthesized by chemical bath deposition (CBD) and subsequent reductive heating, as reported previously [48]. To synthesize the Si@NiOOH nanoflowers, plasma-synthesized Si NPs (20 mg, particle size: 50–100 nm, 99% pure) purchased from Sigma-Aldrich (St. Louis, MO, USA) were dispersed in a beaker containing a mixture of water (4 mL) and ethanol (2 mL) and were sonicated for 2 h (Solution 1). Ni(CH$_3$COO)$_2$·4H$_2$O (0.25 g), and potassium peroxodisulfate (0.05 g) was dissolved in a beaker containing water (4 mL) and ethanol (2 mL) (Solution 2). Solution 1 was mixed with Solution 2 under magnetic stirring at 200 rpm (Solution 3). NH$_4$OH (28–37%, 0.2 mL) was diluted in deionized water (10 mL) and added dropwise (one drop per second) to Solution 3 under stirring. The yellowish solution slowly turned dark after several minutes. The reaction continued for 30 min following the addition of NH$_4$OH, and the precipitate was washed with a large amount of deionized water to remove the adsorbed ions (SO$_4^{2-}$, K$^+$, Ni$^{2+}$, CH$_3$COO$^-$, etc.). The brown Si@NiOOH nanoflowers that were obtained were dried in an oven at 60 °C for 6 h. The dried Si@NiOOH nanoflowers were transformed to NiO-coated Si (Si@NiO) by heating the former under Ar flow in a tube furnace under increasing temperatures up to 350 °C at a heating rate of 2 °C min$^{-1}$. The sample was heated using a temperature control program and then naturally cooled to ambient temperature [48].
2.2. Characterization of Si@NiO Nanoflowers

The morphologies of the Si NPs and Si@NiO nanoflowers were characterized by scanning electron microscopy (SEM; Hitachi SU8230, Hitachi High-Tec, Tokyo, Japan) at an acceleration voltage of 10 kV and transmission electron microscopy (TEM; Tecnai G2 F20 TWIN TMP, FEI, Hillsboro, OR, USA) at 120 kV. Powder X-ray diffraction (PXRD) patterns of the Si NPs and Si@NiO nanoflowers were recorded using a diffractometer (SmartLab, Rigaku, Tokyo, Japan) with Cu Kα radiation and a Ni filter. The voltage and current in the X-ray tube of the diffractometer were maintained at 40 kV and 30 mA, respectively, and the patterns were acquired at a scan rate of 4°/min and at an interval of 0.02°. Fourier-transform infrared (FT-IR) spectra were recorded on a Bio-Rad FTS 135 spectrometer (Hercules, CA, USA) using KBr pellets. Thermal properties were evaluated by thermogravimetric analysis (TGA; TG 209 F3 Tarsus, NETZSCH, Selb, Germany). The specific surface areas of the samples were measured at −196 °C using the Brunauer–Emmett–Teller (BET) method using a 3FLEX surface characterization analyzer and physisorption analyzer (Micromeritics, Atlanta, Georgia, USA). The pore size distribution was measured from the adsorption branch using the Barrett–Joyner–Halenda (BJH) method.

2.3. Electrochemical Properties of Si@NiO Nanoflowers

Electrochemical properties were measured at 25 °C in a traditional three-electrode system using a glassy carbon electrode (GCE) with Si@NiO sample as the working electrode, Ag/AgCl with saturated KCl as the reference electrode, and Pt wire as the counter electrode [49]. Material inks were prepared by mixing 4 mg of Si@NiO and 0.1 mL of 5% Nafion solution (Sigma-Aldrich). The inks were dropped onto a GCE. Cyclic voltammetry (CV) measurements were carried out in phosphate-buffered saline (PBS) with 0.01 M of ascorbic acid (AA) at a scan rate of 100 mV/s and voltage window of 0.0–1.0 V.

2.4. Metal Ion Release from Si@NiO Nanoflowers

The release of metal ions from the Si@NiO nanoflowers on tryptic soy agar plates was tested. Si@NiO (1 mg) was added to 0.9% saline solution (1 mL) and stirred for 6–48 h at 25 °C [50]. This solution was centrifuged at 25 °C and 5000 rpm for 5 min, and the supernatant was separated from the reaction tube. The metal ions that were released in the samples were identified using inductively coupled plasma optical emission spectrometry (ICP-OES; iCAP 7400 ICP-OES Duo, Thermo Fisher Scientific, Waltham, MA, USA).

2.5. Cell Culture

Human breast cancer cell line (MCF-7) and mouse embryonic fibroblasts (MEFs) were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Gibco Laboratories, Grand Island, NY, USA) containing 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 °C in a 5% CO₂ humidified atmosphere. The medium was changed every two days, and the cells were digested with trypsin and were re-suspended in a fresh medium before confluence.

2.6. In Vitro Anticancer Activity

Cell viability was quantitatively determined using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxypenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which is similar to the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and measures the metabolic rates of cells [51,52]. MCF-7 and MEFs were seeded into a 96-well plate (2 × 10⁴ cells per well) in DMEM medium. After 12 h, the medium was replaced with 200 µL of fresh medium containing various concentrations of Si@NiO (0–200 µg/mL). After incubation for 24 h, the Si@NiO-containing media was carefully removed, and the cells were washed twice with PBS. Then, an MTS cell proliferation assay kit solution (20 µL) and fresh medium (200 µL) were added to each well. After incubation for an additional 4 h, the absorbance was measured at 490 nm using a microplate reader (Synergy H1, BioTek, Winooski, VT, USA). The number of proliferating cells was quantified.
using a standard curve of the cells. In addition, the cell viability was quantitatively analyzed using a live/dead assay (ThermoFisher Scientific, Waltham, MA, USA), in which the live and dead cells were identified by green and red fluorescence, respectively [51–53]. For this, MCF-7 and MEFs were seeded in a 48-well plate at a density of 5 × 10^4 cells per well. After 12 h, the medium was replaced with 200 μL of fresh medium containing various concentrations of Si@NiO (0–200 μg/mL). After incubation for 24 h, the cells were rinsed with PBS and were then incubated in PBS containing 4 μM calcein-AM and 2 μM ethidium homodimer-1 (EtBr-1) for 30 min. After washing with PBS, the stained cells were observed using an inverted fluorescence microscope (IX83, Olympus, Center Valley, PA, USA). Cell viability was quantified by calculating the ratio of live cells to the total number of cells.

2.7. Statistical Analysis

All data are expressed as mean ± standard deviation, and experiments were performed at least in triplicate. Statistically significant differences were evaluated using the t-test, and statistical significance was as follows: (*) p < 0.05, (**) p < 0.01, and (***) p < 0.001.

3. Results and Discussion

3.1. Preparation of Si@NiO Nanoflowers

Si@NiO nanoflowers were prepared using a previously reported method [48] with slight modifications, as shown in Figure 1A. During CBD, the Si NPs were encapsulated in porous flower-like NiOOH shells (i.e., Si@NiOOH), which were subsequently reduced to a porous flower-like NiO shell to produce Si@NiO upon mild heating at 350 °C under an argon flow. The SEM and TEM images showed that the Si NPs were spherical, with an average size of 100 nm, while Si@NiO had a flower-like core–shell structure (Figure 1B), where the Si core was uniformly covered by a thin nanoflower-like NiO shell. The flower-like morphology with an open petal structure on the surface was stable and well maintained, even after further annealing. As reported previously [48], the shell layers had a uniform thickness of 10–30 nm, as observed by TEM (Figure 1B, bottom).

Figure 1. Synthesis and characterization of Si@NiO nanoflowers. (A) Schematic representation of the synthesis of Si@NiO nanoflowers. (B) SEM and TEM images of Si NPs and Si@NiO nanoflowers.

3.2. Characterization of Si@NiO Nanoflowers

As shown in Figure 2A, the bright brown color of the Si NPs changed to dark brown after the successive heat treatment of the Si substrate to form Si@NiO. The flower-like Si@NiO species was composed of a core–shell structure in which the Si NPs were wrapped by porous NiO sheets, as evident from the SEM and TEM images in Figure 1B. The PXRD patterns and FT-IR spectra of the Si NPs and Si@NiO were recorded. As shown in Figure 2B, high-intensity diffraction peaks were observed at 2θ values of 28.3°, 47.2°, 55.9°, 75.7°, and 87.9°, corresponding to Si (111), (220), (311), (400), and (331) lattice structure [54], respectively, and additional peaks were observed at 2θ values of 37.1°, 43.3°, and 62.6°, corresponding
to the coated NiO (111), (200), and (220), respectively. (JCPDS Card No. #47-1049). The FT-IR spectrum of Si@NiO (Figure 2C) shows peaks at 685 and 1644 cm⁻¹, corresponding to Ni-O stretching (NiO) and Si-O stretching (SiO₂), respectively. This is consistent with previously reported data [55], emphasizing that Si@NiO is well synthesized from Si NP. The thermal stability of the Si NP and Si@NiO was investigated by TGA, wherein Si@NiO was found to have a high silicon content of 78.6 wt.% (Figure 2D). These observations are consistent with the findings of a previous study [48].

3.2. Characterization of Si@NiO Nanoflowers

As shown in Figure 2A, the Si NPs were wrapped by NiO sheets as evident from the SEM and TEM images in Figure 1B. This is consistent with the findings of a previous study [48]. The PXRD patterns, (Figure 2B), indicating that the Si@NiO nanoflowers were composed of Si (111), (200), and (220) lattice structure [54], respectively. (JCPDS Card No. #47-1049). The FT-IR spectrum of the Si NPs and Si@NiO were recorded. As shown in Figure 2C, the Si@NiO nanoflowers showed FT-IR spectra that were consistent with previously reported data [55], emphasizing that Si@NiO is well synthesized from Si NP. On the contrary, the Si NPs showed negligible N₂ adsorption and a low average pore size (0.56 nm), indicating their low porosity. As shown in Table 1, V₁₀₀, Vₘeso, and Sᵦₑₜ, and the average pore size significantly increased after coating the Si NPs to form Si@NiO. In particular, the larger surface area of Si@NiO, compared to those of Si NPs and other reported absorbents such as MoS₂ and TiO₂, can be expected to provide more favorable sites for easy attachment to cell membranes [56,57].

3.3. Pore Structure Characterization

The pore structure and surface area of the Si NP and Si@NiO nanoflowers were evaluated from the N₂ adsorption–desorption isotherms acquired at −196 °C. The micropore volume (Vᵢ₅₀₀), mesopore volume (Vₘeso), and specific surface area (Sᵦₑₜ) were calculated using the BET method, and the average pore size was measured from the adsorption branch using the BJH method. The N₂ adsorption–desorption isotherms and the corresponding pore size distribution curves are shown in Figure 3A,B, respectively. The N₂ adsorption curves for Si@NiO show a hysteresis loop from 0.5 to 1 (P/P°), indicating that the Si@NiO is rendered highly mesoporous after forming a shell with the NiO petal layers. On the contrary, the Si NPs showed negligible N₂ adsorption and a low average pore size (0.56 nm), indicating their low porosity. As shown in Table 1, Vᵢ₅₀₀, Vₘeso, Sᵦₑₜ, and the average pore size significantly increased after coating the Si NPs to form Si@NiO. In particular, the larger surface area of Si@NiO, compared to those of Si NPs and other reported absorbents such as MoS₂ and TiO₂, can be expected to provide more favorable sites for easy attachment to cell membranes [56,57].

3.4. Electrochemical Properties

The CV curves of Si@NiO were obtained in PBS containing 0.1 M AA (C₆H₅O₂) at a scan rate of 100 mV s⁻¹ in the potential range of 0.0–1.0 V using an Ag/AgCl reference
electrode. The Ni(II) center of the Si@NiO participates in the following redox reaction with AA:

$$\text{Ni}^{2+} + C_6H_8O_6\text{(AA)} \rightarrow \text{Ni} + 2H^+ + C_6H_6O_6$$

Both Si@NiO and Si NPs were easily reduced in the redox reaction with AA, and the positive redox current was higher for Si@NiO than it was for Si NP at low potentials (Figure 4). As Si@NiO was reduced more easily by AA, it could induce reactive oxygen species (ROS) formation more easily than the Si NPs could.

**Figure 3.** Pore structure characterization of Si@NiO nanoflowers. (A) $N_2$ adsorption–desorption isotherms and (B) pore size distribution of Si NPs and Si@NiO based on the BJH method.

**Table 1.** Micro pore volume ($V_{\text{micro}}$), mesopore volume ($V_{\text{meso}}$), specific surface area ($S_{\text{BET}}$), and average pore size of Si and Si@NiO.

| Sample   | $V_{\text{micro}}$ (cm$^3$/g) | $V_{\text{meso}}$ (cm$^3$/g) | $S_{\text{BET}}$ (m$^2$/g) | Average pore size (nm) |
|----------|-------------------------------|-------------------------------|-----------------------------|------------------------|
| Si NP    | 0.006                         | 0.05                          | 23.50                       | 0.56                   |
| Si@NiO   | 0.01                          | 0.59                          | 206.08                      | 6.51                   |

**Figure 4.** Electrochemical characterization. CV curves of Si NP and Si@NiO acquired in PBS containing 0.1 M AA; scan rate: 100 mVs$^{-1}$.

3.5. Ion Release Test

The amount of Ni ions released from the Si@NiO nanoflowers was measured using ICP-OES. Si@NiO degradation was tested at a concentration of 1 mg/mL in 0.9% saline solution at 25 °C for 6, 12, 24, and 48 h. The concentration of Ni(II) ions released from
Si@NiO increased from 8.01 ppm at 6 h to 18.04 ppm after 48 h (Figure 5). Si@NiO was found to be robust, maintaining its flower-like structure well in 0.9% saline solution.

![Figure 5](image_url)  
**Figure 5.** Metal ion release from Si@NiO nanoflowers. Concentration of Ni ions released from 1 mg/mL of Si@NiO in 0.9% saline solution.

3.6. Anticancer Properties and Cytotoxicity

The most important requirements of cancer therapeutics are efficacy and selective toxicity [58,59]. The ability of a drug to induce cancer cell apoptosis without affecting normal cells is the key requirement for effective cancer treatment. Since the active metal ions on the surface of metal oxide nanoflowers can actively participate in ROS formation through oxidation, these nanoflowers have great potential as a therapeutic for cancer treatment. Moreover, as the metal ion release is not sufficiently high enough, this aspect should not affect the anticancer activity remarkably. Nonetheless, it is important to determine the cytotoxicity of Si@NiO nanoflowers on normal cells and cancer cells. The MCF-7 cancer cell line and MEF normal cell line were used for in vitro anticancer tests [58,60]. The results of the MTS assay are shown in Figure 6A. There were no obvious toxic effects on the MEFs in the presence of 0–100 μg/mL Si@NiO MEFs, and the cell viability was higher than 90% after 24 h of incubation. However, at a higher Si@NiO concentration of 200 μg/mL, the viability of these cells decreased to 67%. At this concentration, the nanoflowers can internalize into the MEF cells and affect them by reacting with the low levels of H₂O₂ [60]. Importantly, the viability of the MCF-7 cells decreased and the anticancer activity of Si@NiO against the MCF-7 cells significantly increased depending on the dose of Si@NiO. At the Si@NiO concentrations of 25, 50, 100, and 200 μg/mL, 20%, 29%, 38%, and 62% of cancer cells were killed. The half-maximum inhibitory concentration values (IC₅₀) of Si@NiO are shown in Figure 6B; it is evident that Si@NiO nanoflowers are significantly more toxic to MCF-7 cells than they are to MEF cells, with IC₅₀ values of 147 and 310 μg/mL for the MCF-7 and MEF cells, respectively. We also performed a live/dead assay to reconfirm the cytotoxicity of the Si@NiO nanoflowers on the normal cells and cancer cells. In the range of 0–100 μg/mL Si@NiO, no obvious toxic effect on the MEFs was observed, and the viability was more than 90% after 24 h of incubation. However, at a higher Si@NiO concentration of 200 μg/mL, the viability of the normal cells decreased to 75%. On the other hand, the viability of the MCF-7 cells decreased depending on the dose of Si@NiO. The MCF-7 cell viabilities at 25, 50, 100, and 200 μg/mL of Si@NiO were 81%, 73%, 49%, and 35%, respectively. These observations agree with the results of the MTS assay. It is likely the ROS that were initially produced during the metabolism of O₂ by the living systems derived from the superoxide anion. Generally, cancer cells have higher levels of free radicals than normal cells, and this phenomenon is associated with the increased metabolism of cancer cells and mitochondrial dysfunction. Increased free radical production in cancer cells brings about the biochemical and molecular changes that are necessary for cancer
cells to become resistant to chemotherapy along with the development, proliferation, and metastasis of cancer cells. Increasing reactive oxygen species to a level that causes cytotoxicity in cancer cells can be an effective method for cancer cell removal by active oxygen-mediated apoptosis or by inhibiting cancer cell resistance [61,62]. Therefore, the ROS formed during the reduction of Ni (II) on the surface of the metal oxide (NiO) are more responsible for the toxic effects on the cancer cells than on the normal cells. Considering the ion release capacity discussed in Section 3.5 and the facile formation of ROS on the surface of the nanoflowers (Section 3.4), it can be speculated that the excellent anticancer activity of Si@NiO originates from its high surface area as well as from the potent oxidative capacity of the metal ions on the surface or that are released from the surface of the Si@NiO nanoflowers rather than from the inflow of metal ions released from Si@NiO into the cells.

**Figure 6.** Cytotoxicity and anticancer activity of Si@NiO nanoflowers. (A) Cytotoxicity of Si@NiO toward the MEF and MCF-7 cells after 24 h of incubation. (B) IC50 values of Si@NiO in the MEF and MCF-7 cells. (C) Live/dead staining images of MEFs and MCF-7 after incubation with various concentrations of Si@NiO for 24 h. Positive control: cells cultured in the absence of Si@NiO. NS: not significant, *p < 0.05 and **p < 0.01. Scale bar: 100 µm.

**4. Conclusions**

In this work, Si@NiO nanoflowers were prepared as a novel anticancer agent using a modified CBD process followed by thermal reduction. The surface area, redox reaction with AA, metal ion-release properties, and morphology of these nanoflowers were investigated, and reasonable anticancer activity was justified based on these parameters. The CV data suggested that the ROS formation by the oxidants (i.e., Si@NiO nanoflower) might partly contribute to cancer cell killing. The cancer cell killing could primarily be attributed to the direct contact of the nanoflower surface with the cancer cell membranes or to the ROS species formed by the Ni (II) ions on the surface of the nanoflowers. In this respect, both high surface area and the positively charged metals on the surface might be determinant factors in inhibiting cancer cell growth. The considerable anticancer activity toward the MCF-7 cells and the high biocompatibility with the MEF cells suggest their potential applications in cancer therapy and pharmaceuticals. By the virtue of direct contact with cancer cells, further research on nanoflowers containing various metals is expected to broaden the scope of therapeutic technology.
Author Contributions: Conceptualization, K.G., J.-D.P., J.-S.Y. and D.N.L.; methodology, K.G., J.-D.P., S.L. and D.N.L.; validation, K.G.; formal analysis, K.G., J.-D.P. and S.L.; data curation, K.G., J.-D.P. and S.L.; writing—original draft preparation, K.G., J.-D.P., J.-S.Y. and D.N.L.; writing—review and editing, K.G. and D.N.L.; supervision, J.-S.Y. and D.N.L.; funding acquisition, K.G., J.-S.Y. and D.N.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (2021R1A2C104285, 2017R1A6A3A11030955, 2019R1A2C2086770) and Kwangwoon University in 2021.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data of the study are available from the corresponding author upon reasonable request.

Acknowledgments: The authors would like to thank KBSIs at Daegu and CCRF for the assistance with the SEM, TEM, and XRD measurements.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Cho, K.; Wang, X.; Nie, S.; Chen, Z.G.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14, 1310–1316. [CrossRef] [PubMed]
2. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macro-molecular drug targeting. Adv. Enzym. Regul. 2001, 41, 189–207. [CrossRef]
3. Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48. [CrossRef]
4. Edis, Z.; Wang, J.; Waqas, M.K.; Ijaz, M.; Ijaz, M. Nanocarriers-mediated drug delivery systems for anticancer agents: An overview and perspectives. Int. J. Nanomed. 2021, 16, 1313–1330. [CrossRef] [PubMed]
5. Landesman-Milo, D.; Goldsmith, M.; Leviatan Ben-Arye, S.; Witenberg, B.; Brown, E.; Leibovitch, S.; Azriel, S.; Tabak, S.; Morad, V.; Peer, D. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett. 2013, 334, 221–227. [CrossRef] [PubMed]
6. Chapoy-Villanueva, H.; Martinez-Carlin, L.; Lopez-Berestein, G.; Chavez-Reyes, A. Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. J. BU ON 2015, 20, 1471–1479.
7. Fan, Y.; Chen, C.; Huang, Y.; Zhang, F.; Lin, G. Study of the pH-sensitive mechanism of tumor-targeting liposomes. Colloids Surf. B Biointerfaces 2017, 151, 19–25. [CrossRef]
8. Shi, C.; He, Y.; Ding, M.; Wang, Y.; Zhong, J. Nanoimaging of food proteins by atomic force microscopy. Part I: Components, imaging modes, observation ways, and research types. Trends Food Sci. Technol. 2019, 87, 3–13. [CrossRef]
9. Kesharwani, P.; Gajbiye, V.; Jain, N.K. A Review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33, 7138–7150. [CrossRef] [PubMed]
10. Baeza, A.; Ruiz-Molina, D.; Vallet-Regi, M. Recent advances in porous nanoparticles for drug delivery in antitumoral applications: Inorganic nanoparticles and nanoscale metal-organic frameworks. Expert Opin. Drug Deliv. 2017, 14, 783–796. [CrossRef]
11. Pietro, P.D.; Strano, G.; Zuccarello, L.; Satriano, C. Gold and silver nanoparticles for applications in theranostics. Curr. Top. Med. Chem. 2016, 16, 3069–3102. [CrossRef] [PubMed]
12. Khataji, M.; Zamani, M.; Golizadeh, M.; Bavi, O. Inorganic nanomaterials for chemo/photothermal therapy: A promising horizon on effective cancer treatment. Biophys. Rev. 2019, 11, 335–352. [CrossRef] [PubMed]
13. Perioli, L.; Pagano, C.; Cecconi, M.R. Current highlights about the safety of inorganic nanomaterials in healthcare. Curr. Med. Chem. 2019, 26, 2147–2165. [CrossRef] [PubMed]
14. Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015, 33, 941–951. [CrossRef] [PubMed]
15. Dadgar, N.; Esfahani, M.K.M.; Torabi, S.; Alavi, S.E.; Akbarzadeh, A. Effects of nanoliposomal and pegylated nanoliposomal artemisinin in treatment of breast cancer. Ind. J. Clin. Biochem. 2014, 29, 501–504. [CrossRef]
16. Bobo, D.; Robinson, K.J.; Islam, J.; Thurecht, K.J.; Corrie, S.R. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm. Res. 2016, 33, 2373–2387. [CrossRef]
17. Ventola, C.L. Progress in nanomedicine: Approved and investigational nanodrugs. Pharm. Ther. 2017, 42, 742–755.
18. Lombardo, D.; Kiselev, M.A.; Caccamo, M.T. Smart nanoparticles for drug delivery application: Development of versatile nanocarrier platforms in biotechnology and nanomedicine. J. Nanomater. 2019, 2019, 1–26. [CrossRef]
19. Rezvantalab, S.; Drude, N.J.; Moraveji, M.K.; Güvener, N.; Koons, E.K.; Shi, Y.; Lammers, T.; Kiessling, F. PLGA-based nanoparticles in cancer treatment. Front. Pharmacol. 2018, 9, 1260. [CrossRef]
20. Dang, Y.; Guan, J. Nanoparticle-based drug delivery systems for cancer therapy. *Smart Mater. Med.* 2020, *1*, 10–19. [CrossRef]
21. Yang, X.; Yang, J.; Wang, L.; Ran, B.; Jia, Y.; Zhang, L.; Yang, G.; Shao, H.; Jiang, X. Pharmaceutical intermediate-modified gold nanoparticles: Against multidrug-resistant bacteria and wound-healing application via an electrospun scaffold. *ACS Nano* 2017, *11*, 5737–5745. [CrossRef] [PubMed]
22. Sánchez-López, E.; Gomes, D.; Estebuelas, G.; Bonilla, L.; Lopez-Machado, A.L.; Galindo, R.; Cano, A.; Espina, M.; Etcheto, M.; Camins, A.; et al. Metal-based nanoparticles as antimicrobial agents: An overview. *Nanomaterials* 2020, *10*, 292. [CrossRef] [PubMed]
23. Gopal, J.; Hasan, N.; Manikandan, M.; Wu, H.-F. Bacterial toxicity/compatibility of platinum nanospheres, nanocuboids and nanoflowers. *Sci. Rep.* 2013, *3*, 1260. [CrossRef] [PubMed]
24. Zhu, Z.; Su, M.; Ma, L.; Ma, L.; Liu, D.; Wang, Z. Preparation of graphene oxide–silver nanoparticle nanohybrids with highly antibacterial capability. *Talanta* 2013, *117*, 449–455. [CrossRef] [PubMed]
25. Yao, H.; Jin, L.; Sue, H.-J.; Sumi, Y.; Nishimura, R. Facile Decoration of Au nanoparticles on reduced graphene oxide surfaces via a one-step chemical functionalization approach. *J. Mater. Chem. A* 2013, *1*, 10783–10789. [CrossRef]
26. Deng, C.H.; Gong, J.L.; Zeng, G.M.; Zhang, P.; Song, B.; Zhang, X.G.; Liu, H.Y.; Huan, S.Y. Graphene sponge decorated with copper nanoparticles as a novel bactericidal filter for inactivation of *Escherichia coli*. *Chemosphere* 2017, *184*, 347–357. [CrossRef] [PubMed]
27. Siddiqui, H.; Qureshi, M.S.; Haque, F.Z. Biosynthesis of flower-shaped CuO nanostructures and their photocatalytic and antibacterial activities. *Nanomicro Lett.* 2020, *12*, 29. [CrossRef]
28. Ananth, A.; Dharaneedharan, S.; Soo, H.J.; Heo, M.S.; Boo, J.H. Soft Jet plasma-assisted synthesis of zinc oxide nanomaterials: Morphology controls and antibacterial activity of ZnO. *Chem. Eng. J.* 2017, *322*, 742–751. [CrossRef]
29. Lee, T.C.; Abdullah, H.Z.; Koshy, P.; Idris, M.I. Deposition of novel bioactive nanoflower-like sodium titanate on TiO2 coating via anodic oxidation for biomedical applications. *Mater. Lett.* 2018, *226*, 256–260. [CrossRef]
30. Li, N.; Zeng, C.; Qin, Q.; Zhang, B.; Chen, L.; Luo, Z. Powerful antibacterial activity of graphene/nanoflower-like nickelous hydroxide nanocomposites. *Nanomedicine* 2018, *13*, 2901–2916. [CrossRef]
31. De Jong, W.H.; Born, P.J. Drug delivery and nanoparticles: Applications and hazards. *Int. J. Nanomed.* 2008, *3*, 133–149. [CrossRef] [PubMed]
32. Whitesides, G.M. The ‘right’ size in nanobiotechnology. *Nat. Biotechnol.* 2003, *21*, 1161–1165. [CrossRef] [PubMed]
33. Khan, S.; Ansari, A.A.; Malik, A.; Chaudhary, A.; Syed, J.B.; Khan, A.A. Preparation, antibacterial activity of graphene/nanoflower-like nickelous hydroxide nanocomposites. *J. Trace Elem. Med. Biol.* 2019, *52*, 12–17. [CrossRef] [PubMed]
34. Hao, R.; Xing, R.; Xu, Z.; Hou, Y.; Gao, S.; Sun, S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. *Adv. Mater.* 2010, *22*, 2729–2742. [CrossRef]
35. Kaviyarasu, K.; Manikandan, E.; Kennedy, J.; Jayachandran, M.; Ladchumanandasiivam, R.; De Gomes, U.U.; Maaza, M. Synthesis and characterization studies of NiO nanorods for enhancing solar cell efficiency using photon upconversion materials. *Ceram. Int.* 2016, *42*, 8385–8394. [CrossRef]
36. Kaviyarasu, K.; Raja, A.; Devarajan, P.A. Structural elucidation and spectral characterizations of Co3O4 nanoflakes. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* 2013, *114*, 586–591. [CrossRef]
37. Lokesh, K.; Kavitha, G.; Manikandan, E.; Mani, G.K.; Kaviyarasu, K.; Rayappan, J.B.B.; Ladchumanandasiivam, R.; Sundeepl Aanand, J.; Jayachandran, M.; Maaza, M. Effective ammonia detection using n-ZnO/p-NiO heterostructured nanofibers. *IEEE Sens. J.* 2016, *16*, 2477–2483. [CrossRef]
38. Sasi, B.; Gopchandran, K.G.; Manoj, P.K.; Koshy, P.; Prabhakara Rao, P.; Vaidyan, V.K. Preparation of transparent and semiconducting NiO films. *Vacuum* 2002, *65*, 149–154. [CrossRef]
39. Huh, A.J.; Kwon, Y.J. “Nanobiotics”: A new paradigm for treating infectious diseases using nanoparticles in the antibiotics resistant era. *J. Control. Release* 2011, *156*, 128–145. [CrossRef] [PubMed]
40. Gupta, A.K.; Gupta, M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. *Biomaterials* 2005, *26*, 1565–1573. [CrossRef]
41. Costa, M.; Heck, J.D. Perspectives on the mechanism of nickel carcinogenesis. *Adv. Inorg. Biochem.* 1984, *6*, 285–309. [PubMed]
42. Cai, X.; Lin, M.; Tan, S.; Mai, W.; Zhang, Y.; Liang, Z.; Lin, Z.; Zhang, X. The use of polychrylineimine-modified reduced graphene oxide as a substrate for silver nanoparticles to produce a material with lower cytotoxicity and long-term antibacterial activity. *Carbon* 2012, *50*, 3407–3415. [CrossRef]
43. Pal, S.; Tak, Y.K.; Song, J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium *Escherichia coli*. *Appl. Environ. Microbiol.* 2007, *73*, 1712–1720. [CrossRef] [PubMed]
44. Kyriacou, S.V.; Brownlow, W.J.; Xu, X.H. Using nanoparticle optics assay for direct observation of the function of antimicrobial agents in single live bacterial cells. *Biochemistry* 2004, *43*, 140–147. [CrossRef]
45. Knetsch, M.L.W.; Koole, L.H. New strategies in the development of antimicrobial coatings: The example of increasing usage of silver and silver nanoparticles. *Polymers* 2011, *3*, 340–366. [CrossRef]
46. Ezhillarasi, A.A.; Vijaya, J.J.; Kaviyarasu, K.; Maaza, M.; Ayesharamia, A.; Kennedy, L.J. Green synthesis of NiO nanoparticles using Moringa oleifera extract and their biomedical applications: Cytotoxicity effect of nanoparticles against HT-29 cancer cells. *J. Photochem. Photobiol. B* 2016, *164*, 352–360. [CrossRef]
47. Saghatforoush, L.A.; Mehdizadeh, R.; Chalabian, F. Hydrothermal and sonochemical synthesis of a nano-sized nickel(II) Schiff base complex as a precursor for nano-sized nickel(II) oxide; spectroscopic, catalytic and antibacterial properties. *Transit. Met. Chem.* 2010, 35, 903–910. [CrossRef]

48. Zhang, C.; Kang, T.-H.; Yu, J.-S. Three-dimensional spongy nanographene-functionalized silicon anodes for lithium ion batteries with superior cycling stability. *Nano Res.* 2018, 11, 233–245. [CrossRef]

49. Xia, C.; Yanjun, X.; Ning, W. Facile synthesis of NiO nanoflowers and their electrocatalytic performance. *Sens. Actuators B* 2011, 153, 434–438. [CrossRef]

50. Jo, J.H.; Kim, H.C.; Huh, S.; Kim, Y.; Lee, D.N. Antibacterial activities of Cu-MOFs containing glutarates and bipyridyl ligands. *Dalton Trans.* 2019, 48, 8084–8093. [CrossRef]

51. Gwon, K.; Kim, Y.; Cho, H.; Lee, S.; Yang, S.H.; Kim, S.J.; Lee, D.N. Robust copper metal–organic framework-embedded polysiloxanes for biomedical applications: Its antibacterial effects on mrsa and in vitro cytotoxicity. *Nanomaterials* 2021, 11, 719. [CrossRef] [PubMed]

52. Lee, D.N.; Gwon, K.; Kim, Y.; Cho, H.; Lee, S. Immobilization of antibacterial copper metal–organic framework containing glutarate and 1,2-bis(4-pyridyl)ethylene ligands on polydimethylsiloxane and its low cytotoxicity. *J. Ind. Eng. Chem.* 2021, 102, 135–145. [CrossRef]

53. Gwon, K.; Jo, E.J.; Sahu, A.; Lee, J.Y.; Kim, M.G.; Tae, G. Improved near infrared-mediated hydrogel formation using diacrylated pluronic f127-coated upconversion nanoparticles. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2018, 90, 77–84. [CrossRef] [PubMed]

54. Wang, W.; Favors, Z.; Li, C.; Liu, C.; Ye, R.; Fu, C.; Bozhilov, K.; Guo, J.; Ozkan, M.; Ozkan, C.S. Silicon and carbon nanocomposite spheres with enhanced electrochemical performance for full cell lithium ion batteries. *Sci. Rep.* 2017, 7, 44838. [CrossRef] [PubMed]

55. Chandrasiri, K.W.D.K.; Nguyen, C.C.; Parimalam, B.S.; Jurng, S.Y.; Lucht, B.L. Citric acid based pre-sei for improvement of silicon electrodes in lithium ion batteries. *J. Electrochem. Soc.* 2018, 165, A1991–A1996. [CrossRef]

56. Xia, X.; Wang, Y.; Cui, B.; Zhang, X.; Zhang, D.; Xu, X. Preparation of MoS2 nanoflowers with rich active sites as an efficient adsorbent for aqueous organic dyes. *New J. Chem.* 2020, 44, 4558–4567. [CrossRef]

57. Mali, S.S.; Betty, C.A.; Bhosale, P.N.; Patil, P.S.; Hong, C.K. From nanocorals to nanorods to nanoflowers nanoarchitecture for efficient dye-sensitized solar cells at relatively low film thickness: All Hydrothermal Process. *Sci. Rep.* 2014, 4, 5451. [CrossRef]

59. Whitten, D.L.; Myers, S.P.; Hawrelak, J.A.; Wohlmuth, H. The effect of St John’s wort extracts on CYP3A: A systematic review of prospective clinical trials. *Br. J. Clin. Pharmacol.* 2006, 62, 512–526. [CrossRef]

60. Ranji-Burachaloo, H.; Karimi, F.; Xie, K.; Fu, Q.; Gurr, P.A.; Dunstan, D.E.; Qiao, G.G. MOF-mediated destruction of cancer using the cell’s own hydrogen peroxide. *ACS Appl. Mater. Interfaces* 2017, 9, 33599–33608. [CrossRef]

61. Jiang, L.; Kon, N.; Li, T.; Wang, S.-J.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated activity during tumour suppression. *Nature 2015*, 520, 57–62. [CrossRef] [PubMed]

62. Lee, J.-C.; Son, Y.-O.; Pratheeshkumar, P.; Shi, X. Oxidative stress and metal carcinogenesis. *Free Radic. Biol. Med.* 2012, 53, 743–757. [CrossRef] [PubMed]